Intelligencia combines exceptional data with the computational power of AI to quantify and improve clinical success and to enhance sourcing of external innovation.

Intelligencia's customers - large pharmaceutical companies and biotechs ranging from multi-billion large-cap to emerging preclinical - use Intelligencia's platform to:

- assess the probability of technical and regulatory success (PTRS) of their development programs and minimise any risks.
- optimise trial design and evaluate additional indications for a clinical asset.
- evaluate the relative attractiveness of external assets.
- predict likely future areas of scientific innovation.